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Abstract
Systemic lupus erythematosus (SLE) persists as a chronic inflammatory autoimmune disease and is
characterized by the production of autoantibodies and immune complexes that affects multiple
organs. The underlying mechanism that triggers and sustain disease are complex and involves certain
susceptibility genes and environmental factors. There have been several immune mediators linked
to SLE including cytokines and chemokines that have been reviewed elsewhere(1–3). A number of
articles have reviewed the role of B cells and T cells in SLE(4–10). Here, we focus on role of dendritic
cells (DC) and innate immune factors that may regulate autoreactive B cells.
Types of DC
DC are a heterogeneous group of bone marrow-derived cells that function in
immunosurveillance, antigen-presention and tolerance. DC subtypes may be dictated by
anatomical location or methodologies in culture conditions. This may partly explain some
differences in human DC and mouse DC phenotypes. The general categories of DCs are the
conventional dendritic cells (cDC) and the plasmacytoid dendritic cells (pDC). The cDC
include those found in the skin, in secondary lymph nodes and the spleen. They are subdivided
into two categories, migratory DCs and resident DC. These subsets of DCs have distinct
phenotypes summarized in Table 1.They also reside in mucosal tissues and these DCs have
been discussed elsewhere(11,12). In the skin, there are DCs which may become Langerhans
cells; however, there are other cDC that are derived from monocytes during inflammation(1,
13). These DCs are migratory and upon antigen acquisition, they move to secondary lymph
nodes and the spleen. This migration of DCs involves a complex sequence of molecular signals
dictated by surface receptors, chemokines, cytokines and microenvironments that guide DCs
to proper areas to activate lymphocytes(1). In addition, the CD8a−, CD4+ CD11b+ DCs localize
mostly to the marginal zone and express DCIR2 that presumably targets antigen to the
endocytic pathway and onto MHC class II, thereby activating CD4+ T cells. These CD8− DCs
also express the inhibitory molecule SIRPα which in Langerhan cells controls migration and
they express CD47 which appears to be important for their development(14,15).
Among the cDCs found in the spleen, they are identified by several cell surface markers
including CD11chi, CD8+, CD205+, and MHC II+. Human DCs do not express CD8 or
DEC-205 and murine cDCs are alsoCD8α−, CD205− (16,17). Moreover, the CD8α+ DCs have
been further distinguished based on their lack of expression of the CD4 marker. These
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CD8a+, CD4− DCs reside primarily in the T cell zones and are thought to be more phagocytic
and have a greater capacity for direct presentation and crosspresentation to T cells(17–24).
Conventional DC
cDC are derived from monocytic lineage and reside primarily in epithelial tissues such as the
skin and in different mucosal organs. cDC at these key positions in various tissue allow for the
immunosurveillance against potential invading pathogens. The two main functions of these
DCs are to induce specific adaptive immune responses to pathogens and to maintain self-
tolerance. This immunosurveillance places DCs at the interface of innate immunity and
adaptive immunity.
One of the most studied cDC is the skin DCs and this also includes DCs known as Langerhans
cells. Upon exposure to pathogens or insult, immature DC can recognize foreign material and
phagocytize them. This phagocytosis is not as efficient as professional phagocytes such as
macrophages; however, the main function of DCs carrying antigenic cargo is to migrate to
secondary lymph nodes to activate T cells, particularly naïve T cells. This migration of DC
and the molecular traffic signals are covered in a recent review(1). These DCs are positive for
the lectin langerin and they express high levels of MHC class II molecules(16,25). In mice,
langerin is expressed at low levels on CD8a+ CDs in lymphoid organs and on a subset of DCs
in the lungs.
The CD8+ lymphoid cDCs as well as B cells are thought to be important in maintaining self
tolerance or specific immune response to pathogens. However, lupus pathogenesis is thought
to arise from these APCs possibly through abnormal antigen-processing or inappropriate
presentation causing excessive stimulation of autoreactive T cells. Autoreactive T cells to
nuclear antigens such as DNA and histones or small ribonucleoproteins including Smith (Sm)
antigens, U1 and heterogeneous ribonucleoprotein (hnRNP) A2 have been associated with SLE
(26–30). These autoreactive T cells may provide help to B cells and promote the activation of
autoreactive B cells from anergy(6). However, many studies on T and B cell tolerance use
model systems that may apply to normal B cells and not necessarily autoreactive B cell that
may have other requirements for anergy or activation(10). Interestingly, recent studies have
focused a T cell-independent induction and regulation of autoreactive B cells.
Plasmacytoid DCs
pDCs have the prominent feature of producing type I interferon (IFN I)(31–33). The typical
phenotype of human pDC is shown in Table 1 and this is somewhat in contrast to the murine
pDC (34–39). Both pDC upregulate MHC II and costimulatory molecules and can activate T
cells(40). These pDC appear to be geared towards immunity against viruses and bacteria
because they express primarily TLR7 and TLR9 which senses components of RNA complexes
and DNA (particularly CpG sequences) respectively in endosomal compartments(41–46).
However, pDC do not express TLR2, TLR3, TLR4, or TLR5. pDC are low in numbers in the
blood of SLE patients; however, the large amounts of IFN I in lupus is attributed to activated
pDC in the lymph nodes, skin or target organs(47–50). This copious production of IFN I is
triggered by the formation of nucleic acid bound to antibodies (immune complex) which are
internalized via FcγRIIa into endosomes. Subsequently, the nucleic acids are detected by TLR7
or TLR9 within the endosomal compartment and results in pDC activation and IFN I secretion
(Figure 1). In addition, one negative signaling pathway utilizes CD303, C-type lectin, and
FcRγ-chain to inhibit transcription of IFN-I and IFN-I responsive genes in human pDCs(51).
In comparing TLR9 function of pDC versus cDC, TLR9 is critical for the activation and
survival of pDCs whereas it appears dispensible for activation of cDC(52). Using a TLR9
ligand, CpG DNA-stimulated pDCs deficient in NFkB1 and C-Rel produced IFN I but not IL-6
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or IL-12 and underwent apoptosis(52). This finding was consistent with reports that TLR9-
deficient, Fas-deficient, lupus-prone mice were inhibited in anti-dsDNA and anti-chromatin
autoantibody production(53). However, anti-Sm antigen antibody (a marker of SLE) was
maintained or increased in TLR9−/− mice. It is likely that TLR7, a receptor for the
ribonucleoprotein Sm antigen, is functionally intact in TLR9−/− mice and can respond by
producing antibody to the Sm autoantigen. Despite the reduction in anti-dsDNA antibody,
TLR9−/− lupus-prone mice maintained a hyperimmune phenotype and autoimmune
pathologies. Contrary to these finding in TLR9−/− lupus-prone mice, TLR7−/− lupus-prone
mice showed decreased lymphocyte and pDC activation, decreased serum IgG and ameliorated
autoimmune disease(54). Thus, TLR7 and TLR9 appear to have different roles in the
development of murine lupus and these studies suggest autoantibody production dependent on
TLR7 may have a greater impact on disease. Subsequent to these studies of TLR9, a second
group suggested the absence of TLR9 on the MRL/lpr background exacerbated autoantibody
production and pathology; thus, TLR9 is not required for pathogenesis and it appears to provide
protection(55). The difference in results could be due to the greater number of backcrosses
onto the MRL/lpr background; hence, a greater number of disease susceptibility loci would be
operating(55). These two studies suggest TLR9 may provide protection versus exacerbation
of autoimmune disease depending on the genetic background of the lupus-prone mice.
Nonetheless, when pDC become activated, they are known to express the chemokine receptor,
CXCR3, which directs them to sites of inflamed lymph nodes(56–58). It is interesting that
some autoreactive B cells from SLE patients also express CXCR3 and may also home to sites
of inflammation(59).
When considering the activation of pDC, the same stimulants must be considered in the context
of B cell activation as well. From SLE patients, a large proportion of B cells expressing TLR9
correlated with high anti-DNA autoantibodies(60). In murine B cells, subsequent TLR9-
MyD88-dependent signaling is critical for class switching to pathogenic IgG antibodies. (61)
The absence of TLR7 or TLR9 or the simultaneous blocking of TLR7 and TLR9 signaling in
B cells inhibited the development of autoantibodies(54,61,62). Thus, at least in B cells, TLR7
and TLR9 along with the BCR signaling appear to activate B cells and promote autoimmunity.
Follicular DCs
A separate category of cells known as follicular dendritic cells (FDC) reside primarily in
germinal centers of secondary lymphoid tissues and function to trap antigen for B cell
stimulation(63,64). FDC have a number of varying cell surface markers that are partly shown
in Table 1 and they retain immune complexes holding antigens using Fcγ receptors or
complement receptors and facilitate the selection of high affinity antibodies; although, high
affinity maturation can occur in the absence of detectable immune complexes on FDCs(65–
67). Recent imaging using two-photo microscopy demonstrated FDC that acquired labeled hen
egg lysozyme (HEL) antigen engage cognate B cells for an average of 3 minutes(68). These
B cells possessed BP-3+ fragments of FDCs on their surface indicating the likelihood of antigen
capture. In addition, FDC have protected B cells in germinal centers from apoptosis by the
provision of Notch ligands and BAFF to promote B cell survival(69). Whether FDC acquire
self-antigens and engage autoreactive B cells in this manner is not clear; however, the presence
of apoptotic material has been detected on the surface of FDCs in a subgroup of patients with
SLE(70). Consistent with this concept, a recent report suggests FDC are essential for induction
of autoantibody in a model of arthritis(71). Moreover, MFG-E8-secreting FDC have recently
been shown to be critical for the removal of apoptotic cells (AC) by tingible-body macrophages
that are in close proximity(72). Defects in clearing dying B cells may provide an environment
conducive to ample autoantigens (See Figure 1). In biopsied samples from case studies of SLE
lymphodenopathy, a number of patients exhibited a disarray of their FDC network suggesting
FDC may be related to disease induction(73).
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Phagocytosis by DC and SLE
One feature found in many patients with SLE is the presence of dying cells in lymph nodes
and various tissues(70,74). This manifestation is a result of either cells dying more frequently
or an inability to clear the AC. It is plausible that during injury, oxidative stress or infection
by pathogens, the abundance of dying cells may be overwhelming and exposure to large doses
of autoantigen may break tolerance. On the other hand, an inability to ingest even normal daily
turnover of cells may render one susceptible to autoimmune responses. Cells dying by apoptosis
provide efficient notification of their impending death by expression of inner plasma membrane
molecules such as phosphatidylserine (PS) which become inverted onto the outer membrane
(75). Furthermore, cells undergoing apoptosis release lysophosphatidylcholine or other factors
which attracts phagocytes to dying cells(76,77). Proper clearance of apoptotic cells is thought
to prevent exposure of self antigens and inhibit the activation of immune cells. In contrast,
primary necrotic cells release different chemical signals such as the nuclear DNA-binding
protein, high mobility group box 1 protein (HMGB1), hyaluronic acid, uric acids which attract
phagocytes and trigger inflammation(78,79). Therefore, the defects in engulfment of ACs in
some SLE patients and in lupus-prone animals suggest more self antigens are available for DCs
to activate autoreactive B cells.
Upon engagement with PS on ACs, several receptors on phagocytes trigger recognition and
engulfment(75). This engulfment of cells in the early stages of apoptosis activates the
phagocyte to secrete IL-10 and TGF-β which promote an anti-inflammatory state(75,80). In
fact, it has recently been shown that ACs administered to mice prevented endotoxic shock by
binding to LPS, reducing proinflammatory cytokines and by suppressing neutrophil infiltration
into target organs; however, a majority of studies on immune modulation by AC have been on
macrophages(81). Interestingly, an emerging area is the role of AC in shaping DC function in
cancer and SLE.
It is apparent that clearing ACs is important so that cytosolic and nuclear self-components of
dying cells are prevented from being released into the interstitial compartments to sensitize
autoreactive T or B cells. Furthermore, proinflammatory cytokines produced by DCs such as
IL-1, IL-12 and TNF-α are actively inhibited by exposure to AC(82–84). However, if ACs are
not adequately cleared, dying cells enter late stage apoptosis or a secondary necrosis stage
which releases not only nucleosomes, snRNPs, and DNA, but also exposure of HMGB1-
nucleosome complexes and other signals to trigger inflammation(85–87). Earlier evidence
suggested HMGB1 was released by primary necrotic cells and induced inflammation whereas
ACs undergoing secondary necrosis bound HMGB1 tightly to chromatin and did not trigger
inflammation(88). However, HMGB1 has been implicated in SLE and more recently, an
alternative mechanism has been proposed for immune activation by HMGB1 from secondary
necrotic cells. HMGB1 from secondary necrotic cells requires binding to nucleosomes to
induce activation of DCs and macrophages which results in the secretion of proinflammatory
cytokines and autoantibodies(87). Free HMGB1 from viable cells or nucleosomes without
HMGB1 were not able to activate DCs or induce cytokine production. This HMGB1-
nucleosome response was mediated by TLR2 but not TLR4, TLR9 or RAGE even though
HMGB1 can bind TLR4 and RAGE(87). One additional note, DCs from SLE patients that
were defective in engulfment of ACs were also poor at regulating IL-12 producing three-fold
more than normal controls, had higher levels of CD86 and were poor at generating tolerizing
DCs(89). Interestingly, HMGB1 was shown to bind to PS and prevent phagocytosis of
apoptotic neutrophils(90). It is plausible that HMGB1 in SLE patients may be binding to PS
on ACs thereby preventing adequate engulfment and inhibition of DCs or other phagocytes
(90).
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Several studies have identified multiple receptors that regulate ingestion of ACs by
macrophages; however, there are fewer reports for mechanisms that are employed by DCs.
CD8+ CD11c+ DC phagocytize debris more efficiently and are the cells responsible for
ingestion of AC whereas CD8− CD11c+ DC do not phagocytize AC(91,92). The ingestion of
ACs by CD8+ DC is facilitated by their expression of DEC205 and CD36 and DC, NK lectin
group receptor-1 (DNGR-1)(91–93). One of the earlier described ligand that bound apoptotic
cells was C1q and it is produced by macrophages and DCs(94). C1q can directly opsonize ACs
and it is recognized by calreticulin or CD91 on phagocytes(95). C1q is thought to suppress DC
activity and the lack of C1q or other complement components results in autoantibody formation
in humans and murine models(96). Furthermore, other receptors that trigger ingestion of ACs
have been shown to be different for DC versus macrophages(97). Macrophages rely
predominantly on Mertk, a cell surface receptor tyrosine kinase; in contrast, DCs do not utilize
Mertk but rather involve other family receptors, Axl and Tyro3(97,98). The use of Axl and
Tyro3 as phagocytic receptors for the ingestion of ACs is much slower taking nearly 6 hours
whereas macrophages engulf dying cells within 15–30 minutes(97). The impact of the delayed
uptake of ACs by DCs is not fully known; however, despite not being used as a phagocytic
receptor, Mertk appears to influence DC deactivation including downregulating IL-12 when
exposed to ACs (See Figure 1)(82,83). This illustrates the complexity of receptors engaged in
clearing ACs and the multiple signaling consequences that regulate subsequent immune
responses. It is plausible that defects in the downstream Mertk-signaling pathways may be
occurring in some patients with SLE.
The phagocytosis mediated by Mertk on macrophages appears to involve phosphorylation of
vav1 or αvβ5 integrin to induce actin rearrangement(99,100). In transfected cell lines, Mertk
associates with integrin αvβ5 which recruits FAK and facilitate phagocytosis by activating
Rac1; however, it is not known whether a similar association is absent in DCs and accounts
for the lack of function of Mertk as a phagocytic receptor(99). Complementarily, the αvβ5
ligand, MFG-E8, also recognizes PS and tingible-body macrophages are responsible for
removal of excess B cells in germinal centers (See Figure 1)(101,102). In mfg-e8−/− mice, lack
of removal of apoptotic B cells in the germinal centers resulted in autoantibody production
(101,103,104). Interestingly, FDC are the critical producers of MFG-E8 which provide
tingible-body macrophages the bridging ligand to ingest dying B cells. Consistent with this
finding, LTα−/− mice that lack FDC also lack MFG-E8 and suffer from autoimmunity(72).
These experimental observations may correlate with reduced phagocytosis of ACs by tingible-
body macrophages from SLE patients(70,74). It is not clear whether Axl and Tyro3 used by
DC interact with integrins to modulate phagocytosis; however, these receptors appear critical
for TLR regulation and cytokine suppression using a negative feedback loop initiated by Axl-
IFNR-I(105). Lastly, scavenger receptor A (SRA) blockade has shown dramatic inhibition of
phagocytosis of ACs by macrophages. It was later demonstrated that SRA associates with
Mertk to signal ingestion(106). Without SRA, engulfment by 60 min is only delayed and not
abrogated. This suggests engulfment is similar to wild type macrophage and that other
molecules are likely activating Mertk. It is not clear whether SRA is important for DC
phagocytosis.
Mice deficient in this family of Mertk, Axl and Tyro3 receptors result in autoantibody
presumably due to their inability to adequately clear ACs(107–109); however, our recent data
suggest Mertk may be the critical receptor responsible for the autoimmune phenotype since
induction of ACs were adequately cleared in wild type, axl−/− or tyro3−/− mice but not
mertk−/− mice(97). Furthermore, the induction of Mertk expression upon binding of ACs is
dependent upon a transcription factor, liver X receptor (LXR)(110). Mice deficient in LXR-
signaling possessed macrophages incompetent in the engulfment of ACs, produced
autoantibodies and displayed autoimmune phenotype. This is very similar to Mertk-deficient
mice(107,109). The role of LXR in DCs was not examined but LXR agonists did not affect
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expression of Axl or Tyro3. Thus, the regulation of Mertk is separate from Axl and Tyro3 and
may suggest possible functional differences in DCs also.
ACs expressing PS are bound by several ligands including GAS6 or protein S. In addition to
being critical for blood coagulation cascades, these factors act as a molecular bridge to bind
Axl and Tyro 3 on DCs or Mertk on macrophages to initiate phagocytosis. GAS6 can bind all
three receptors having greater affinity for Axl and less for Tyro3 or Mertk(111). Interestingly,
GAS6-deficient mice do not show obvious autoimmunity suggesting it is not an essential factor
and that other bridging molecules such as MFG-E8 may be more important given it is a ligand
for αvβ5 and appears to work in conjunction with Mertk to facilitate phagocytosis of ACs
(99,104,112). In contrast, deletion of protein S results in embryonic lethality (E17.5) in mice
and the precise role in autoimmunity has not been determined; however, protein S is important
for phagocytosis of ACs and low expression of protein S or anti-protein S antibodies have been
detected in patients with SLE(102,113–115). Early reports for protein S have been confusing
in studies using reagents from different species. Protein S was found to engage Tyro3 and it
does not bind Axl nor Mertk; however, a recent report suggest auto-oxidation of cysteine
residue in protein S results in dimerization and this is a prerequisite for binding to Mertk on
human macrophages(116,117). In contrast to findings in murine macrophages which expressed
all TAM family members, the human macrophages expressed only Mertk. In that study, DCs
were not examined; however, murine DCs apparently do not require Mertk for engulfment of
ACs, utilize Axl and Tyro3 to engulf ACs and produce protein S but not GAS6(97,98). As part
of this model for DC engulfment of ACs, GAS6 is produced by dying thymocytes but they do
not produce protein S(83). If Axl recognizes GAS6 but not protein S and Tyro3 binds protein
S but with less affinity to GAS6, then it is plausible that GAS6 provided by ACs could facilitate
interaction with Axl and complement DC-derived protein S to bind Tyro3 to engulf ACs.
Further experimentation will be necessary to corroborate the interaction of DCs with ACs.
The receptors involved in AC engulfment not only drive autoimmunity, but, the interaction of
DCs with ACs or their intermediate ligands has consequences on DC maturation and function.
PS inhibited the upregulation of HLA molecules on human DCs, inhibited secretion of IL-12,
and reduced their ability to stimulate T cells(84). A number of receptors may be participating
in the recognition and engulfment; however, it is not clear which combination may be
regulating maturation and cytokine suppression. CD36 and αvβ3 are known to participate in
macrophage engulfment of ACs but not in the regulation of cytokine secretion(118). Also,
CD36, αvβ3, or αvβ5 integrins highly expressed on CD8+ DCs does not influence cross
presentation or cross tolerance(92,119). However, cross-linking of CD36 has been shown to
suppress human DC activation of T cells and induce the secretion of IL-10. In the murine
system, Mertk has been implicated as a major regulator of NFkB in DCs and inhibitor of IL-12
(82). In addition, expansion of DC populations may contribute to autoimmunity. LAG3 was
originally described in regulating lymphocyte expansion; however, it has been recently found
on pDC but was not expressed on cDCs(120). The function of LAG3 on pDCs appears to be
in the regulation of proliferation and expansion but does not affect maturation markers.
Role of Type I Interferon
There is an association of IFNI found in the serum of patients with SLE(79,121). Further link
for a role of IFNI was made from observations of patients receiving IFN treatment for viral
infection or tumor therapy(122,123). A fraction of these patients had detectable autoantibodies
and a few developed autoimmune symptoms. In addition, reviews on IFNI suggest it has
powerful roles in shaping immune responses in SLE by affecting lymphocyte, macrophage,
DC and NK activation(124,125). Thus, understanding the critical signaling pathways that lead
to a break in tolerance and autoimmunity may be difficult given the pleotrophic affects of IFNI.
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TLR ligands that recognize CpG DNA (TLR9), RNA (TLR6 & TLR7) are often associated
with human pDCs. When macrophages are activated by TLR ligands, IFNI is upregulated either
in an autocrine or paracrine manner. Interestingly, IFNI has been shown to induce the
expression of Axl in macrophages(126). In DCs, TLR4 stimulation upregulates IFNI and a
complex of Axl and IFNR-I(105). Axl-IFNR-I complex bind IFNI and induces Stat-1 which
subsequently activates suppressor of cytokines (SOCS) genes, SOCS-1 and SOCS-3(105,
126). The SOCS proteins in turn, associate with various intracellular signaling molecules to
inhibit TLR-mediated activation of DCs(127). Furthermore, Axl activation after binding to
GAS6 has been shown to be a chemotactic and survival signal for human DCs(128). This
suggests that IFNI and Axl signal transduction pathways may have multiple functions including
the regulation of DC immune responses. Because several self-DNA, RNA and nucleic acids
from pathogens can trigger various TLR signaling, it is thought infectious agents or endogenous
nucleic acids may be one environmental cue that triggers SLE.
A second important mechanism for the activation of DC is by immune complexes (IC) formed
by autoreactive antibodies and nuclear components(129,130). These IC are captured by pDC
as mentioned above and upon Fc receptor-mediated internalization, TLRs activate the pDC to
secrete IFNI. Furthermore, IC can also be captured by FDCs and may be a source of
autoantigens for naïve autoreactive B cells. If autoreactive B cells die after not receiving
survival signals, FDCs secrete MFG-E8 which aids in phagocytosis of ACs by nearby tingible-
body macrophages(72). Thus, pDC, FDC and macrophages cooperate in an intimate
relationship to rid germinal centers of ACs.
Key experiments have shown IFNI is important in the development of autoantibody production
(131–133). In different murine models of SLE, deletion of the IFNR-I results in diminished
autoantibody titers and disease(124,134–136). Several cytokines, chemokines and
upregulation of various receptors on B cells, T cells and innate immune cells have been
associated with models of lupus. It is not clear which population of DC is pivotal in regulating
the autoimmune phenotype; however, IFNI responsive genes offer clues. Several labs have
embarked on studies using microarrays and proteomics to identify downstream genes that may
be associated with the development of lupus. Recently, nearly half the SLE patients were found
to have upregulated IFN responsive genes in peripheral blood mononuclear cells(137).
Consistent with the important link of IFNI, TYK2 and IRF5 were pulled from SNP analysis
in a population of patients with SLE(138,139). TYK2 associates with the IFNRI and with JAK1
to initiate STAT activation(140). In addition, IRF5 is found in B cells and DCs, and IRF5 is
activated by certain TLRs to induce IFNI(141). Thus, these polymorphisms appear to have a
logical link for a role of IFNI in the pathogenesis of SLE.
The high levels of serum IFNI has been associated with SLE(48,130,142–144). The high levels
of IFN has been correlated with increase activation of T cells by DCs(145). The trigger for
IFNI secretion by pDC can be IgG-opsonized ACs mediated through FcγRIIa, ICs containing
anti-dsDNA antibodies bound with DNA, ICs containing RNA bound antibodies, or DNA
derived from ACs, implicating autoantibodies in IFNI production(129,146,147). This secretion
of IFNI along with IL-6 and CD40 has been shown to induce B cells differentiation into plasma
cells; however, B cells may also differentiate in the absence of CD40 ligation(148,149). More
recently, apoptotic blebs rather than ACs were ingested readily and stimulated pDC to mature
by increasing CD86 and CD40 expression along with production of IL-6 and TNFα(150). In
addition, IFNI can promote class isotype switching by stimulating DCs(151).
Interferon and TLRs
It has been speculated that SLE symptoms are exacerbated by infection-induced or UV-induced
apoptotic cells and this may trigger IFNI production, particularly in cutaneous lupus
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erythematosus(47,61,152). Nucleic acid exposure is thought to activate DCs, macrophages and
B cells. A body of evidence includes TLR3, TLR7, TLR9 as important receptors for the
activation of innate immune cells and the secretion of IFNs(153,154). Furthermore, a greater
proportion of B cells and monocytes from SLE patients have been shown to express TLR9
(60). In addition, one recent report indicates TLR4 activation requires IRF7 and partly IRF5
signaling, and this results in IFNα production whereas IFNβ IRF3 in murine cDC and human
monocytes(155,156). Thus, it is plausible that bacterial infections may trigger acute symptoms
in SLE; however, it is not clear why IFNI would then result in flares(155). Interestingly, IRF5
has been associated with SLE whereas IRF4 may be protective by competing for IRF5 in TLR
signaling. In a similar protective manner, lower expression of IRF3 due to a polymorphism in
the promoter suggests lower risk of SLE(157). Experimentally, the role of TLRs in
autoimmunity have been extensively studied and reviewed elsewhere(6). Lastly, IRAK1 is a
TLR downstream signal intermediate and is a risk gene for SLE(153,158). IRAK1 has been
associated with sle1 or sle3 disease loci and sle3 possess hyperactive DCs that manifests in
increased T cells activity(159). Mating of IRAK1-deficient mice with B6.sle3 mice reduced
CD80 expression on DCs and reduced TNFα production to TLR3 and TLR9 agonists(158). It
is thought that the lack of IRAK1 inhibited the DCs and resulted in diminished autoantibody
production. Therefore, several TLR-signaling factors may prompt or control the induction of
SLE and adds to the difficulty in predicting individuals prone to developing SLE.
Interferon and HIN 200 Family
Though several mechanisms can induce IFNI and promote SLE, the molecular pathways are
only partly understood. One important link to the IFN pathway is the discovery of the HIN200
family of IFN-inducible genes(160). This gene cluster have been associated with autoimmune-
prone mice(161). One in particular has come to the forefront, p202 (IFI202)(162). In the NZB
and (NZB×NZW)F1 mice, multiple genes contribute to the autoimmune phenotype(163,164).
A prominent locus from backcrossed mice termed Nba2 is associated with autoantibody
production. Expression profiling found p202 and p203 in the Nba2 interval of B6 congenic
mice; however, only p202 was highly expressed in B cells and nonlymphocytes(162).
Furthermore, p204 was not highly expressed in spleen cells from B6.Nba2 mice and it was
found that p202 was expressed in NZB parent mice but not NZW or nonautoimmune B6 splenic
cells. This suggested that p202 gene may be linked to autoreactive B cells and may be involved
in breaking tolerance checkpoints in B cell maturation and survival(6,9,160,165). Interestingly,
we have found p202 expression in DCs and macrophages (unpublished data) and this suggest
that antigen-presenting cells may be affected by p202. Moreover, another HIN200 family
member, AIM2, has been associated with caspase-dependent cytoplasmic DNA-mediated
macrophage death and p202 has been recently shown to counter this cell death(166–169). DCs
may have a similar mechanism to deal with self-DNA and pathogen-associated DNA but under
aberrant conditions of SLE, this form of self-limitation of infections may be defective. Thus,
hyper-activated DCs that over-express p202 could survive longer than necessary and they may
result in prolonged engagement with autoreactive B cells which may contribute to
autoimmunity. Indeed, defects in DC apoptosis in mice deficient in BIM or mice specifically
deleted of Fas or a caspase inhibitor p35 in DCs, developed autoimmunity presumably due to
DC accumulation, hyperactivation of lymphocytes and autoantibody production(170–172).
Interestingly, a contrary report suggested engagement of FAS on DC actually causes the
induction of chemokines and they become activated to survive rather than die(173). In fact,
Axl/IFNR has been implicated in the chemotaxis and survival of human DCs and this may
have implications in SLE patients that are characterized by high levels of IFNI(128). IFNI
stimulation increased Axl expression on immature DCs and in the presence of the Axl ligand,
GAS6, these DCs were rescued from growth factor deprivation-induced apoptosis.
Furthermore, GAS6 pretreatment of differentiating DCs prevented LPS responses and inhibited
the production of cytokines. This may be linked to earlier observations that PS also inhibited
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human DC maturation and reduced T cell stimulation(84). It is plausible that exposure to ACs
may allow survival of these DCs and increase a likelihood of stimulating autoreactive B cells.
It is possible too that ACs may inhibit DC maturation and they therefore can’t activate T
regulatory cells or repress autoreactive T cells. Thus, defects in clearing ACs may lead to a
lack of DC inhibition and maturation which may result in overactive immature DCs that can’t
activate regulatory T cells nor repress autoreactive B cells.
DC regulating B cells
DCs activate naïve T cells extraordinarily well due to their high surface expression of MHC
and costimulatory molecules. However, evidence suggests that T-independent activation of
autoreactive B cells may occur in extrafollicular areas of the spleen(6). DC may interact with
low affinity autoreactive B cells that may be regulated by different principles. There are ample
reports regarding the DCs maintaining central and peripheral T cell tolerance but alternative
mechanisms must be operating to explain circumstances involving T-independent autoreactive
B cells(4,174–178). We mentioned above how pDCs or FDCs may contribute to the induction
of autoantibodies. In addition, DCs and macrophages may activate naïve B cells by providing
IFNI, IL-6 and BAFF(179,180). In contrast, recent studies suggested TLR-stimulated
macrophages and DCs imparted regulatory activities on autoreactive B cells(181,182). These
reports suggested that DCs and macrophages release IL-6 and sCD40L locally which inhibited
antibody production from autoreactive follicular B cells. This suppressive affect by DC (and
macrophages) required close proximity to the autoreactive follicular B cells; however, this
suppression is temporary as removal of these secreted ligands reversed the inhibition.
Interestingly, marginal zone (MZ) B cells were only inhibited by sCD40L from macrophages.
Thus, autoreactive B cells chronically exposed to antigen behave differently that conventional
B cells and may respond to IL-6 through reprogramming of intracellular signaling mechanisms
(10). This repressive effect by DC required B cells to be chronically stimulated with antigen.
Coincidentally, DCs and macrophages have been shown to possess autoantigens on their cell
surface presumably from apoptotic or necrotic cells. These DCs could be providing nearby
autoreactive B cells with a source of self antigen and suppressive factors to impose a state of
anergy. Furthermore, whether autoreactive B cells are repressed may depend on their
anatomical location in lymphoid tissues(7). MZ B cells may be repressed by sCD40L secreted
by MZ macrophages but when activated, the B cells may move to periarteriolar lymphoid
sheaths (PALS) where they encounter DCs and become repressed by IL-6(182). In
autoimmune-prone MRL/lpr mice, DCs and macrophages cannot repress autoreactive B cells
due to defects in IL-6/sCD40L secretion(183). Thus, TLR-activated DCs appear to regulate B
cells not only through T cell-mediated regulatory mechanisms, but they may impact
autoreactive B cells directly by their provision of antigen and secretion of IL-6 and sCD40L.
Whether this model of DC/macrophage-induced tolerance of autoreactive B cells occurs in
certain patients with SLE remains to be examined.
Summary
DCs subtypes have individual functions and appear to influence multiple processes that may
activate or repress autoreactive B cells. Part of their influence is dictated by their receptor and
cytokine profiles and by their location. The checkpoints for regulating autoreactive B cells
which may be different than conventional B cells may be due to changes in activation threshold,
the hyperimmune phenotype under IFNI stimulation, or their response to negative regulators
such as repression by TNFα, IL-6 and sCD40L which can be produced by properly activated
DCs or macrophages. The observation that an abundance of IFNI in SLE patients and work in
murine models suggest IFN-responsive genes may play a significant role in the development
of SLE. From studies of lupus-prone mice, it appears that multiple points that regulate
autoreactive B cells are defective allowing for the maturation of autoreactive B cells. In
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addition, the potential of DCs surviving longer may disrupt normal engagement of autoreactive
B cells, thus skewing B cells towards antigen- activation of autoreactive B cells rather than
repressing them. Although the characterization of DC and affect on B cells have contributed
greatly to our understanding of tolerance, further studies involving DCs from lupus-prone
models and autoreactive B cells may provide new insights.
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General model for potential roles of DCs in the regulation of autoreactive B cells in secondary
lymphoid tissues. Normal immune homeostasis regulates autoreactive B cells. Plausible
mechanisms that inhibit autoreactive B cells include B cell anergy due to a block in BCR
signaling or to repression of chronically stimulated follicular B cells from the local production
of IL-6, TNFα and CD40L by DCs and macrophages or marginal zone (MZ) B cells by
macrophages. ACs may suppress DCs and macrophages from becoming hyperactive. Defects
in clearing ACs by DCs and macrophages increase self antigens available to B cells and releases
checks in DC (or macrophage) activity or survival. In addition, nucleic material from pathogens
or ACs maybe endocytosed or they may form antigen-antibody immune complexes (IC) that
bind Fc receptors (FcR) on several cell types and are internalized into endosomes. TLR7 and
TLR9 sense RNA or DNA complex components and trigger IFNI (type I interferon) secretion
particularly by pDC. High levels of IFNI production is associated with increased p202 that
may affect several cells including B cells and FDC in germinal centers as well as cDC. The
activated FDC have been shown to secrete MFG-E8 which binds PS on ACs and αvβ5 integrin
on tingible-body macrophages to facilitate ingestion. Similarly, GAS6 binds both PS on ACs
and Mertk on macrophages and cooperates with αvβ5 to facilitate efficient engulfment of dying
cells. In addition, complement C1q deficiency results in impaired clearance by macrophages
via CD91 and autoantibody formation. The lack of MFG-E8, Mertk or C1q results in
autoantibody formation in animal models. The FDCs can also provide immune-complexed self
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antigens to autoreactive B cells. In the presence of IFNI, B cells will upregulate TLR7 or TLR9
and sufficient BCR and TLR stimulation may break tolerance of autoreactive follicular B cells.
These follicular B cells migrate out into the circulation to become memory B cells or antibody-
secreting cells. In the MZ, cDC may also become activated by IFNI and nuclear material which
promotes cytokine production. These activated cDC may sufficiently stimulate BCR-, BAFF-,
and TLR-mediated activation of MZ B cells that then migrate through the follicle to become
antibody-secreting cells in the bridging channels or red pulp.
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